Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

Last updated: March 26, 2025
Sponsor: ModernaTX, Inc.
Overall Status: Active - Recruiting

Phase

1/2

Condition

Distal Renal Tubular Acidosis

Treatment

mRNA-3927

Clinical Study ID

NCT04159103
mRNA-3927-P101
2022-502910-10
2022-502910-10-00
  • All Genders

Study Summary

This First-in-Human (FIH) Phase 1/2 study is designed to characterize the safety, tolerability, and pharmacological activity (as assessed by biomarker measurements) and to determine the optimal dose of mRNA-3927 in participants with genetically confirmed propionic acidemia (PA). After establishing a dose with acceptable safety and pharmacodynamic (PD) response in a Dose Optimization Group (Part 1) in participants ≥1 year of age, additional participants will be enrolled into the study in a Dose Expansion Group (Part 2) to allow for further characterization of the efficacy, safety, and PD of mRNA-3927. Part 3 will evaluate the safety, efficacy and PD response of mRNA-3927 in infants (<1 year of age).

Eligibility Criteria

Inclusion

Inclusion Criteria:

Participants ≥1 year of age are eligible to be included in the study only if all of the following criteria apply:

  • ≥ 8 years of age at the time of consent/assent if enrolled as 1 of the first 2participants in Part 1.

  • ≥1 year of age at the time of consent/assent if enrolled after the first 2participants.

  • Confirmed diagnosis of PA based on diagnosis by molecular genetic testing (PCCAand/or PCCB mutations).

  • Part 2 only: At least one documented MDE in the 12-month period before consent.

Participants <1 Year of Age :

  • Identification by newborn screening shortly after birth or having suspected PA bypresenting with a spectrum of metabolic symptoms, and having a sibling diagnosedwith PA. Participant may enter the Screening Period while awaiting genetic testingresults, provided that all other eligibility criteria are met but would not beenrolled until diagnosis of PA is confirmed.

  • ≥37 weeks gestational age at the time of birth without otherconditions/comorbidities that in the opinion of the Investigator may interfere withthe interpretation of study results.

  • Body weight ≥3 kg at Screening.

  • At least 1 documented PA-related event prior to Screening defined as the followingcriteria:

  • Clinical signs of metabolic deterioration consistent with PA (eg, vomiting, notfeeding well/poor suck, heavy breathing, lethargy, absence of proper perfusion,abnormal movements including bicycling, abnormal tone, low body temperature,seizure[s]), OR

  • Meeting the criteria of MDE definition, OR

  • Evidence of laboratory abnormalities as evidenced by at least one of thefollowing:

  • Metabolic acidosis (decreased pH) with high anion gap, or compensated metabolicacidosis (reduced bicarbonate, or base deficit, or reduced PaCO2 or increasedlactate) with high anion gap.

  • Acute hyperammonemia.

  • Neutropenia or thrombocytopenia.

Exclusion

Exclusion Criteria:

Participants of all ages are excluded from the study if during Screening any of the following criteria apply:

  • Any individual with laboratory abnormalities achieving theresholds defined in theprotocol

  • Estimated glomerular filtration rate (eGFR) <30 milliliters (mL)/minute/1.73 squaremeter (m^2) for participants of all ages receiving chronic dialysis.

  • History of organ transplantation or planned organ transplantation during the periodof study participation.

  • Corrected QT interval (QTc) >480 milliseconds (ms) using Bazett's correction.

  • Grade 3 or 4 heart failure according to the Modified Ross Heart FailureClassification for Children or the New York Heart Association Classification.

  • Pregnant or breastfeeding.

  • Other clinically significant conditions that in the Investigator's opinion couldinterfere with the safety of the participant, the interpretation of study results,or limit the participation in the study.

Study Design

Total Participants: 68
Treatment Group(s): 1
Primary Treatment: mRNA-3927
Phase: 1/2
Study Start date:
April 15, 2021
Estimated Completion Date:
January 31, 2026

Study Description

During the Dose Optimization Stage, after each dose cohort is fully enrolled (≥1 year of age), , and the dose-limiting toxicity (DLT) observation window of at least 14 days is complete for the final participant in that cohort, the Sponsor will review the totality of available safety data in conjunction with all available PK/PD data. Based on this review, the Sponsor will recommend a revised dose and/or dosing interval. The Sponsor will abide by predefined constraints as to the maximum percentage change in dose and dose interval. A maximum of 9 cohorts will be enrolled in Part 1 (Dose Optimization).

Upon establishment of a dose with acceptable safety and PD activity in a Dose Optimization Part (Part 1), additional participants (≥1 year of age) will be enrolled into the study in a Dose Expansion Part (Part 2) to allow for further characterization of the safety, efficacy, and PD of mRNA-3927. Part 3 will evaluate the safety, efficacy and PD response in infants (<1 year of age).

Participants in all the phases will participate in a predosing observational period, followed by a treatment period, and then a follow-up period after withdrawal of treatment.

Connect with a study center

  • Stollery Children's Hospital University of Alberta

    Edmonton, Alberta T6G 2R7
    Canada

    Active - Recruiting

  • Hospital For Sick Children

    Toronto, Ontario M5G 1X8
    Canada

    Active - Recruiting

  • Fujita Health University Hospital

    Toyoake-shi, Aichi 470-1192
    Japan

    Active - Recruiting

  • Tohoku University Hospital

    Sendai-Shi, Miyagi 980-8574
    Japan

    Active - Recruiting

  • Birmingham Children's Hospital

    Birmingham, B4 6NH
    United Kingdom

    Site Not Available

  • University Hospital Birmingham NHS Foundation Trust

    Birmingham, B15 2TH
    United Kingdom

    Active - Recruiting

  • Great Ormond Street Hospital (GOSH)

    London, WC1N 3JH
    United Kingdom

    Active - Recruiting

  • Great Ormond Street Hospital for Children NHS Foundation Trust

    London, WC1N 3JH
    United Kingdom

    Active - Recruiting

  • Manchester University NHS Foundation Trust

    Manchester, M13 9WL
    United Kingdom

    Active - Recruiting

  • Willink Biochemical Genetics Unit

    Manchester, M13 9WL
    United Kingdom

    Active - Recruiting

  • David Geffen School of Medicine UCLA

    Los Angeles, California 90095
    United States

    Active - Recruiting

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California 90095
    United States

    Active - Recruiting

  • Lucile Packard Children's Hospital Stanford

    Stanford, California 94304
    United States

    Active - Recruiting

  • University of Stanford Medical Center

    Stanford, California 94304
    United States

    Active - Recruiting

  • Johns Hopkins Hospital

    Baltimore, Maryland 21287
    United States

    Active - Recruiting

  • Johns Hopkins Hospital, Adult Outpatient Clinical Research Unit

    Baltimore, Maryland 21287
    United States

    Completed

  • Boston Children's Hospital

    Boston, Massachusetts 02115
    United States

    Completed

  • University of Michigan

    Ann Arbor, Michigan 48109
    United States

    Active - Recruiting

  • University of Michigan Hospitals

    Ann Arbor, Michigan 48109
    United States

    Active - Recruiting

  • Icahn School of Medicine at Mount Sinai - Clinical Research Unit

    New York, New York 10029
    United States

    Active - Recruiting

  • Duke University Medical Center

    Durham, North Carolina 27710
    United States

    Active - Recruiting

  • Duke University Medical System (Duke Health)

    Durham, North Carolina 27710
    United States

    Active - Recruiting

  • Cincinnati Children's Hospital

    Cincinnati, Ohio 45229
    United States

    Active - Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio 45229
    United States

    Completed

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania 19104
    United States

    Active - Recruiting

  • Children's Hospital of Philadelphia (CHOP)

    Philadelphia, Pennsylvania 19104
    United States

    Active - Recruiting

  • Texas Children's Hospital

    Houston, Texas 77030
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.